All In Biotech

Drug Trial Radar · NCT01016015

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas

Last checked: Nov 20, 2026Latest source record: Jul 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

178

Actual

Start

Nov 2009

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Sponsor type
NIH
First posted
Nov 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth by blocking the ability of tumor cells to grow and spread. Giving temsirolimus with cixutumumab may be an effective treatment for soft tissue or bone sarcoma.

Conditions

  • Metastatic Osteosarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Osteosarcoma
  • Stage III Adult Soft Tissue Sarcoma
  • Stage IV Adult Soft Tissue Sarcoma

Interventions

  • CixutumumabBiological

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • TemsirolimusDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Rate, Defined as CR + PR + SD, as Assessed by RECIST CriteriaTime frame: From study entry until recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death or date of last contact, assessed at 12 weeks

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Decatur Memorial Hospital

    Decatur, Illinois

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois

  • Memorial Medical Center

    Springfield, Illinois

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland

  • University of Michigan University Hospital

    Ann Arbor, Michigan

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • SUNY College at Old Westbury

    Old Westbury, New York

  • Albert Einstein College of Medicine

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • M D Anderson Cancer Center

    Houston, Texas

  • Virginia Commonwealth University/Massey Cancer Center

    Richmond, Virginia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.